| Literature DB >> 21185798 |
Barbara Westerhaus1, Aidar R Gosmanov, Guillermo E Umpierrez.
Abstract
The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. In order to determine the beneficial effect of insulin secretagogues as a class in diabetes prevention, we performed a literature search for randomized controlled studies and review articles on diabetes prevention and use of sulfonylureas, nateglinide, and meglitinide in PubMed and Ovid Medline since 1950. Three studies were identified with none of them reporting success in preventing diabetes, indicating that insulin secretagogues should not be recommended for diabetes prevention.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21185798 PMCID： PMC3746508 DOI： 10.1016/j.pcd.2010.11.002
Source DB: PubMed Journal: Prim Care Diabetes ISSN： 1878-0210 Impact factor: 2.459